ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 151 filers reported holding ARGENX SE in Q4 2019. The put-call ratio across all filers is 0.59 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $8,262,000 | -6.4% | 30,000 | 0.0% | 0.18% | -12.4% |
| Q4 2020 | $8,823,000 | -16.0% | 30,000 | -25.0% | 0.21% | -48.0% |
| Q3 2020 | $10,501,000 | -33.4% | 40,000 | -42.9% | 0.40% | -32.9% |
| Q2 2020 | $15,766,000 | +49.6% | 70,000 | -12.5% | 0.60% | +22.9% |
| Q1 2020 | $10,538,000 | -34.4% | 80,000 | -20.0% | 0.49% | -23.6% |
| Q4 2019 | $16,052,000 | +10.0% | 100,000 | -21.9% | 0.64% | -27.9% |
| Q3 2019 | $14,599,000 | -31.3% | 128,110 | -14.6% | 0.89% | -27.1% |
| Q2 2019 | $21,237,000 | -38.1% | 150,000 | -45.5% | 1.22% | -47.4% |
| Q1 2019 | $34,331,000 | -20.6% | 275,000 | -38.9% | 2.32% | -33.9% |
| Q4 2018 | $43,232,000 | +200.0% | 450,000 | +136.8% | 3.51% | +274.6% |
| Q3 2018 | $14,410,000 | -37.6% | 190,000 | -31.8% | 0.94% | -45.1% |
| Q2 2018 | $23,079,000 | +3.0% | 278,536 | 0.0% | 1.71% | +2.3% |
| Q1 2018 | $22,405,000 | +22.4% | 278,536 | -4.0% | 1.67% | -12.9% |
| Q4 2017 | $18,311,000 | – | 290,000 | – | 1.92% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 273,343 | $106,529,967 | 17.42% |
| Kynam Capital Management, LP | 184,300 | $71,827,239 | 9.88% |
| Ikarian Capital, LLC | 132,100 | $51,483,333 | 8.20% |
| Avoro Capital Advisors LLC | 1,263,500 | $492,423,855 | 6.68% |
| Artia Global Partners LP | 46,438 | $18,098,282 | 6.24% |
| DCF Advisers, LLC | 25,700 | $10,016,061 | 5.29% |
| Bellevue Group AG | 923,284 | $359,831,473 | 5.13% |
| Eagle Health Investments LP | 64,400 | $25,098,612 | 4.69% |
| Paradigm Biocapital Advisors LP | 150,000 | $58,459,500 | 4.52% |
| Paradigm Biocapital Advisors LP | 142,259 | $55,442,600 | 4.28% |